SCHEMBL2832979

SCHEMBL2832979

CCCC[N+]1(C)CCCC1.COS(=O)(=O)[O-]

nearest known ligand 0.42

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 2/20 0.42
LMNA P02545 3/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.40
TSHR P16473 2/20 0.38
BLM P54132 2/20 0.38
APOBEC3A P31941 2/20 0.38
APOBEC3G Q9HC16 2/20 0.38
CYP3A4 P08684 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PMP22 Q01453 1/20 0.38
RECQL P46063 2/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
EPHX2 P34913 1/20 0.35
GNAI3 P08754 1/20 0.35
GNAO1 P09471 1/20 0.35
GNAI1 P63096 1/20 0.35
CDC25A P30304 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9719402 0.92 LMNA (0.49) BBOX1LMNAKMT2AKDM4ETSHR
SCHEMBL23573880 0.89 KDM4E (0.42) BBOX1LMNAKMT2AKDM4ETSHR
Sulfuric Acid SCHEMBL17102671 0.89 BBOX1 (0.47) BBOX1LMNAKMT2AKDM4ETSHR
Sulfuric Acid SCHEMBL21195064 0.87 BBOX1 (0.46) BBOX1LMNAKMT2AKDM4ETSHR
SCHEMBL1715741 0.87 BBOX1 (0.46) BBOX1LMNAKMT2AKDM4ETSHR
SCHEMBL3047547 0.86 RECQL (0.41) BBOX1LMNAKMT2AKDM4ETSHR
SCHEMBL16908414 0.85 BBOX1 (0.44) BBOX1LMNAKMT2AKDM4ETSHR
Sulfuric Acid SCHEMBL21195044 0.85 BBOX1 (0.44) BBOX1LMNAKMT2AKDM4ETSHR
Sulfuric Acid SCHEMBL17102627 0.85 BBOX1 (0.48) BBOX1LMNAKMT2AKDM4ETSHR
SCHEMBL17102598 0.85 CDC25A (0.49) TSHRBLMAPOBEC3AAPOBEC3GRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY INC (US) 2021-12-23 US claimed
EP-2577003-B1 METHOD AND APPARATUS FOR OPERATING A STEAM CYCLE PROCESS WITH A LUBRICATED EXPANDER MAN TRUCK & BUS AG (DE) 2018-07-18 EP claimed
US-9382816-B2 Method and apparatus for operating a steam cycle process with a lubricated expander MAN TRUCK & BUS AG (DE) 2016-07-05 US claimed
US-20150335547-A1 ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS COLGATE-PALMOLIVE COMPANY (US) 2015-11-26 US claimed
EP-2934469-A2 ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS Colgate-Palmolive Company (US) 2015-10-28 EP claimed
WO-2014098871-A2 ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS COLGATE-PALMOLIVE COMPANY (US) 2014-06-26 WO claimed
US-20130341561-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY, INC. (US) 2013-12-26 US claimed
US-20130263598-A1 Method and Apparatus for Operating a Steam Cycle Process with a Lubricated Expander MAN TRUCK & BUS AG (DE) 2013-10-10 US claimed
EP-2577003-A2 METHOD AND APPARATUS FOR OPERATING A STEAM CYCLE PROCESS WITH A LUBRICATED EXPANDER MAN Truck & Bus AG (DE) 2013-04-10 EP claimed
US-7718579-B2 Electrochemical deblocking using a hydrazine derivative COMBIMATRIX CORPORATION (US) 2010-05-18 US claimed
EP-1869061-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY Combimatrix Corporation (US) 2007-12-26 EP claimed
EP-1805206-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE Combimatrix Corporation (US) 2007-07-11 EP claimed
US-20070034513-A1 Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array COMBIMATRIX CORPORATION 2007-02-15 US claimed
WO-2007006418-A1 IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-01-18 WO claimed
WO-2006131234-A1 COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-12-14 WO claimed
WO-2006105037-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY COMBIMATRIX CORPORATION (US) 2006-10-05 WO claimed
WO-2006031814-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE COMBIMATRIX CORPORATION (US) 2006-03-23 WO claimed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US claimed
US-20240101999-A1 HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS THERMO FISHER SCIENTIFIC GENEART GMBH (DE) 2024-03-28 US disclosed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY DNMT1, DNASE1, DNPEP BBOX1 796/4885LMNA 2697/4885KMT2A 3944/4885
US-20150335547-A1 ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS MCOLN3, TAS2R39, TAS2R40 BBOX1 4846/4885LMNA 1795/4885KMT2A 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.